Navigation Links
Angiotech announces positive results from Bio-Seal(TM) clinical study
Date:3/9/2009

VANCOUVER, March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced positive clinical study results for its Bio-Seal(TM) Lung Biopsy Tract Plug System at the Society of Interventional Radiologists Annual Scientific Meeting in San Diego, CA. The trial assessed the safety and efficacy of Bio-Seal in patients undergoing lung biopsy procedures and demonstrated a statistically significant clinical benefit in the group receiving BioSeal.

"We are extremely pleased that the Bio-Seal treatment arm hit the primary end point of clinical success," said Dr. William Hunter, President and CEO of Angiotech. "These results indicate that Bio-Seal improves the existing technology used to diagnose lung cancer by significantly reducing the rates of pneumothorax."

The purpose of this clinical study was to assess the safety and efficacy of an expanding hydrogel plug in reducing pneumothorax rates associated with CT-guided lung biopsy. The prospective, randomized, controlled clinical study enrolled and randomized 339 investigational patients at 15 different investigational sites. Inspiratory upright chest x-rays were performed at 30 to 60 minutes, 24 hours and 30 days after treatment. The Bio-Seal treatment arm hit the primary end point of clinical success, absence of pneumothorax at each time period. Based on the per-protocol population, clinical success rate was 85% using Bio-Seal and 69% in the control group. This difference was statistically significant (p=0.002). Although not powered for statistical analysis, positive trends were also observed for Bio-Seal subjects as compared to the control group in various secondary endpoints, including fewer Bio-Seal subjects admitted to the hospital for pneumothoraces (9.4% vs. 13.6%), fewer chest tubes placements in Bio-Seal patients (3.5% vs. 10.7%), and fewer additional chest x-r
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., , SAN DIEGO, Nov. 20 Veri...l Award in the mid-size company category at the 20...nsored by the San Diego Society for Human Resource...nal human resources practices. ,, Veridiam was ...mployee-nominated companies, honored at the recent...
(Date:11/20/2009)... METTLER TOLEDO recently ...ctions Process Optimization Using At-Line Particle...ember 2, 2009. In this webinar, the application o...d to map the design space and optimize a series of...s, flow rates, and roller compaction forces. , ...
(Date:11/19/2009)..., , BLAUVELT, N.Y., Nov. 19 ...eat germ extract, responds to a press release issu...the Hungarian company for making false and self-se...n BioSciences. ,, Dr. Hidvegi stated from his ...a claim that research on Avemar does not apply to ...
(Date:11/19/2009)..., , MUNSTER, Germany, November 19 /P... they have filed on November 16th, 2009 Flibanseri...duced dyskinesia in Parkinson,s,disease for orphan...es Agency,(EMEA). Levodopa-induced dyskinesia is a...d Parkinson,s and a serious burden to some of thos...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Roller Compaction Process Optimization Using At-Line Particle Characterization 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... April 22 Renovis, Inc.,(Nasdaq: RNVS ), today a...dvisory firm, has joined ISS/Risk Metrics in recom...erger agreement with Evotec AG (Frankfurt,Stock Ex...cheduled for May,1, 2008. In the proposed merger, ...ed into the right to receive the equivalent of 1.0...
...il 22 Medarex, Inc.,(Nasdaq: MEDX ) announced to...Stanley Global Healthcare Unplugged Conference at ...vent will be webcast live and will be,available in...site at, http://www.medarex.com . An archived edit...g the event., About Medarex, Medarex is a biopha...
...il 22 Sysmex America, Inc. today,announced the su...ton, OH),beta studies for its integrated hematolog...solution, which combines the Sysmex HST-N hematolo...s, Inc. VARIANT(TM) II TURBO,Link, enables on-dema...setting. "This integrated testing solution, now fu...
Other Biology Technology:Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 2Glass Lewis & Co. Recommends Renovis Shareholders Vote For Merger With Evotec 3Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 2Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 3Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution 4
(Date:11/23/2009)... existed for 360 million years and survived when t...hreatening to make many of them extinct, according...ogy Today . , The fungus, Batrachochytrium den...waves of amphibian extinctions in Central America ...cts over 350 amphibian species by penetrating thei...
(Date:11/23/2009)...Institute for Child Health Research has found evid...tion in pregnancy affects child behaviour in diffe...nline in the international journal Addiction . ,...s drawn from a random sample of more than 2000 mot...ter the baby,s delivery, and were then followed up...
(Date:11/23/2009)..., posing dangers to human health and the environme... new project with funding from the U.S. Environmen...nd grease that contribute to millions of overflows...s to further reduce the risk of sewage spills. , ...ems, as opposed to "combined" systems that also ha...
Breaking Biology News(10 mins):New study links alcohol in pregnancy to child behavior problems 2Lose the fat: Targeting grease to curtail sewer overflows 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 1DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 3BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 1BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 2BioWa and NKTT Announce Licensing of BioWas POTELLIGENT 28R 29 Technology For Use in Antibody Research and Development 14560 3Delcath Systems Inc Completes Phase III Study Enrollment 5635 1Delcath Systems Inc Completes Phase III Study Enrollment 5635 2Delcath Systems Inc Completes Phase III Study Enrollment 5635 3
...chnologies that allow scientists to quickly and ac... analysis are being creatively deployed for the fi.... , The University of Ghana, supported by the Phi...oneering the use of DNA "barcodes" to map menacing...atic filariasis (LF), commonly known as elephantia...
... Germany, April 29, 2009 / b3c newswire / - K...d its Cellular Target Profiling® technology to...r target of celecoxib (Celebrex®, Pfizer). Cel... inhibitor approved for the treatment of osteoarth...ition, celecoxib’s anti-proliferative effect...
...n University and the Donald Danforth Plant Science...ion from the U.S. Department of Energy (DOE) to do...lion, the Washington University award is the large...illion for the Donald Danforth Plant Science Cente...d. , Washington University and the Donald Danfort...
Other Biology News:DNA barcoding of mosquito species deployed in bid to end elephantiasis 2DNA barcoding of mosquito species deployed in bid to end elephantiasis 3DNA barcoding of mosquito species deployed in bid to end elephantiasis 4KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2DOE makes largest Danforth Campus research award in history 2DOE makes largest Danforth Campus research award in history 3DOE makes largest Danforth Campus research award in history 4DOE makes largest Danforth Campus research award in history 5
Nitrite Colorimetric Assay Kit from Molecular Probes (Invitrogen)
...ologies has been at the forefront providing advanc...ry and application of genomic information. Whether...100 or 100,000 custom oligos for microarray applic... exacting synthesis, purification, QA/QC and docum...
Cultrex 3D Culture Matrix BME from R&D Systems
Sentrix Custom-96 Expression Array Matrix (1) from Illumina
Biology Products: